Fig. 1From: Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjectsArithmetic mean plasma concentration–time profiles of lucerastat in healthy subjects after administration of a single oral dose of 100, 300, 500, and 1000 mg lucerastat, or two oral doses of 1000 mg lucerastat separated by 12 h (linear and semilogarithmic scales, 0–48 h). (Per–protocol set)Back to article page